|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
834
|
|
pubmed:dateCreated |
1995-7-17
|
|
pubmed:abstractText |
The prognosis of patients with metastatic adrenal cortical carcinoma is poor, and their disabling symptoms are usually unresponsive to conventional therapy. A patient with Cushing's syndrome secondary to a secretory adrenal cortical carcinoma was treated with octreotide, endocrine therapy and chemotherapy having failed. Treatment led to a dramatic relief of her symptoms with a fall in corticosteroid secretion. Somatostatin analogue therapy for this tumour should be encouraged in view of the lack of alternative palliative treatment.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0032-5473
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
71
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
229-30
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:7540300-Adrenal Cortex Neoplasms,
pubmed-meshheading:7540300-Cushing Syndrome,
pubmed-meshheading:7540300-Female,
pubmed-meshheading:7540300-Humans,
pubmed-meshheading:7540300-Hydrocortisone,
pubmed-meshheading:7540300-Middle Aged,
pubmed-meshheading:7540300-Octreotide,
pubmed-meshheading:7540300-Palliative Care,
pubmed-meshheading:7540300-Testosterone,
pubmed-meshheading:7540300-Time Factors,
pubmed-meshheading:7540300-Treatment Outcome
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
Secretory symptoms from metastatic adrenal cortical carcinoma responding to octreotide.
|
|
pubmed:affiliation |
Department of Clinical Oncology, Hammersmith Hospital, London, UK.
|
|
pubmed:publicationType |
Journal Article,
Case Reports
|
